In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

However, shares of the U.S. drugmaker fell about 12% in premarket trading after it reported data from its oral weight loss ...

Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2025. "Lilly delivered another quarter ...

Eli Lilly and Co. (LLY) on Thursday reported second-quarter profit of $5.66 billion. The Indianapolis-based company said it had net income of $6.29 per share.

The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year ...

As households combining three-plus generations become more common, advisors have an opportunity to address their needs.

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...

Redditors are complaining their long-term Mounjaro use is causing their hair to fall out in clumps. Experts claim sorting your diet out may fix the issue.